vTv Therapeutics Inc. (VTVT)


+0.01 (+1.00%)
Symbol VTVT
Price $0.7979
Beta -1.106
Volume Avg. 0.11M
Market Cap 65.016M
Shares () -
52 Week Range 0.382-1.4
1y Target Est -
DCF Unlevered VTVT DCF ->
DCF Levered VTVT LDCF ->
ROE 0.17% Neutral
ROA -0.06% Neutral
Operating Margin -
Debt / Equity -255.11% Sell
P/E -2.96 Sell
P/B -3.50 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest VTVT news

Mr. Paul J. Sekhri M.Sc., MSc
NASDAQ Capital Market

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.